Literature DB >> 23918288

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013.

C Camps1, E Felip, R García-Campelo, J M Trigo, P Garrido.   

Abstract

Lung cancer remains the most commonly diagnosed cancer worldwide and the leading cause of cancer-related mortality. More than 80 % of all newly diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). Despite recent advances, 40 % of patients still have advanced disease at the moment of diagnosis. Clinical information, pathological diagnosis and molecular assessment are needed to guide the systemic therapy, whereas discussion within an experienced team is key to adequately select the most appropriate multidisciplinary strategies. The purpose of this article is to provide updated recommendations for the management of these patients.

Entities:  

Mesh:

Year:  2013        PMID: 23918288     DOI: 10.1007/s12094-013-1085-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  37 in total

1.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

2.  Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis.

Authors:  J P Pignon; L A Stewart
Journal:  Cancer       Date:  1996-06-01       Impact factor: 6.860

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  European trends in preoperative and intraoperative nodal staging: ESTS guidelines.

Authors:  P De Leyn; D Lardinois; P Van Schil; R Rami-Porta; B Passlick; M Zielinski; D Waller; T Lerut; W Weder
Journal:  J Thorac Oncol       Date:  2007-04       Impact factor: 15.609

5.  Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Authors:  Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

6.  Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).

Authors:  Pilar Garrido; Javier de Castro; Ángel Concha; Enriqueta Felip; Dolores Isla; Fernando López-Ríos; Luis Paz-Ares; José Ramírez; Julián Sanz; José Javier Gómez
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

7.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

10.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

Authors:  Andrea Ardizzoni; Luca Boni; Marcello Tiseo; Frank V Fossella; Joan H Schiller; Marianne Paesmans; Davorin Radosavljevic; Adriano Paccagnella; Petr Zatloukal; Paola Mazzanti; Donald Bisset; Rafael Rosell
Journal:  J Natl Cancer Inst       Date:  2007-06-06       Impact factor: 13.506

View more
  8 in total

Review 1.  Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art.

Authors:  Ángel Artal Cortés; Lourdes Calera Urquizu; Jorge Hernando Cubero
Journal:  Transl Lung Cancer Res       Date:  2015-04

2.  SEOM guidelines 2013: a response to the needs of Spanish oncologists.

Authors:  J J Cruz-Hernández; C A Rodríguez
Journal:  Clin Transl Oncol       Date:  2013-08-08       Impact factor: 3.405

Review 3.  Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  E Felip; Á Concha; J de Castro; J Gómez-Román; P Garrido; J Ramírez; D Isla; J Sanz; L Paz-Ares; F López-Ríos
Journal:  Clin Transl Oncol       Date:  2014-10-29       Impact factor: 3.405

Review 4.  Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  A Gómez; J A González; F Couñago; C Vallejo; F Casas; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2015-08-18       Impact factor: 3.405

Review 5.  Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.

Authors:  Corey A Carter; Karen Zeman; Regina M Day; Patrick Richard; Arnold Oronsky; Neil Oronsky; Michelle Lybeck; Jan Scicinski; Bryan Oronsky
Journal:  Oncotarget       Date:  2016-06-28

6.  SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer.

Authors:  G Fernández-Pérez; R Sánchez-Escribano; A M García-Vicente; A Luna-Alcalá; J Ceballos-Viro; R C Delgado-Bolton; J C Vilanova-Busquets; P Sánchez-Rovira; M P Fierro-Alanis; R García-Figueiras; J E Alés-Martínez
Journal:  Clin Transl Oncol       Date:  2017-12-18       Impact factor: 3.405

Review 7.  Molecular biomarkers in early stage lung cancer.

Authors:  María Rodríguez; Daniel Ajona; Luis M Seijo; Julián Sanz; Karmele Valencia; Jesús Corral; Miguel Mesa-Guzmán; Rubén Pío; Alfonso Calvo; María D Lozano; Javier J Zulueta; Luis M Montuenga
Journal:  Transl Lung Cancer Res       Date:  2021-02

8.  The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review.

Authors:  Yu Jie Chen; Ling Xiao Chen; Mei Xiang Han; Tian Song Zhang; Zhi Rui Zhou; Dian Sheng Zhong
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.